Effros R B, Hulette C M, Ettenger R, Dillard L C, Zeller E, Duong R, Walford R L
J Immunol. 1986 Sep 1;137(5):1599-603.
In this report, we describe the production and characterization of the first human-human hybridoma secreting antibody to HLA Class II determinants. The hybridoma (GMEC101), which has been stable in tissue culture for greater than 20 mo, secretes 10 to 50 micrograms/ml of IgM-kappa antibody. This antibody binds to a wide range of human cell lines, but not to the HLA-A,B,C, and DR-negative K562 cell line. Functionally, GMEC101 strongly inhibits a unidirectional mixed lymphocyte reaction (MLR) at the level of the stimulator cell. Neither the cellular ELISA binding nor the MLR inhibition is lost after a triple platelet absorption (which removes Class I but not Class II activity). Because the binding and MLR blocking show no correlation with the known DR or DQ specificities, we suggest that GMEC101 may be detecting a novel HLA Class II determinant.
在本报告中,我们描述了首例分泌针对人类白细胞抗原(HLA)Ⅱ类决定簇抗体的人-人杂交瘤的制备及特性鉴定。该杂交瘤(GMEC101)在组织培养中已稳定超过20个月,分泌10至50微克/毫升的IgM-κ抗体。此抗体可与多种人类细胞系结合,但不与HLA-A、B、C以及DR阴性的K562细胞系结合。在功能上,GMEC101在刺激细胞水平强烈抑制单向混合淋巴细胞反应(MLR)。经过三次血小板吸附(去除Ⅰ类活性但不影响Ⅱ类活性)后,细胞酶联免疫吸附分析(ELISA)结合及MLR抑制活性均未丧失。由于结合及MLR阻断与已知的DR或DQ特异性无关,我们认为GMEC101可能检测到一种新的HLAⅡ类决定簇。